Hims says it will stop selling GLP-1 pill, after legal pressure from USnews2026-02-07T20:24:40+00:00February 7th, 2026|Endpoints News|
#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMSnews2026-02-07T20:15:33+00:00February 7th, 2026|Endpoints News|
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and morenews2026-02-07T11:00:05+00:00February 7th, 2026|Endpoints News|
US calls for DOJ investigation of Hims over GLP-1 drugsnews2026-02-06T23:08:43+00:00February 6th, 2026|Endpoints News|
TrumpRx launch falls flat for some, citing generic accessnews2026-02-06T21:01:47+00:00February 6th, 2026|Endpoints News|
HHS drops legal fight over blocked 340B rebate pilotnews2026-02-06T19:19:31+00:00February 6th, 2026|Endpoints News|
Orphan drug tweak in US spending bill will make life easier for the FDAnews2026-02-06T19:10:15+00:00February 6th, 2026|Endpoints News|
Agomab, SpyGlass cap biggest week for biotech IPOs since 2021news2026-02-06T16:26:57+00:00February 6th, 2026|Endpoints News|
Biogen CEO says Alzheimer’s drug Leqembi on track for continued growthnews2026-02-06T16:11:57+00:00February 6th, 2026|Endpoints News|
UniQure pauses higher doses in Fabry study; Aro shares Pompe datanews2026-02-06T15:00:12+00:00February 6th, 2026|Endpoints News|
